Current Trials

FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (cancer that typically occurs in the urinary system).

The purpose of this trial is to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy.

Non-metastatic breast, colorectal, gastro-oesophagal or prostate cancer which can be treated and potentially cured.

The purpose of this study is to evaluate the the effects of aspirin on disease recurrence and survival in patients who have had primary curative therapy for common non-metastatic solid tumours.

Early stage breast cancer

This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab.

Ovarian cancer

The purpose of this study is to investigate if two medications; Rucaparib and Nivolumab used together or separately are better than the current best available treatment for patients who have had platinum-based chemotherapy for ovarian cancer.

Children, adolescents, and young adults with Classic Hodgkin Lymphoma whose disease has come back or did not respond to initial treatment.

The purpose of this study is to determine whether certain drug combinations are safe and effective.

Adenovirus infections in high-risk paediatric allogenic hematopoietic cell transplant recipients

Assess the safety, overall tolerability, and antiviral activity of “short course” BCV therapy, 

Indolent (grow slowly) Non-Hodgkin’s Lymphoma that have returned after previous treatment.

The purpose of this study is to evaluate the efficacy and safety of copanlisib in combination with standard immunochemotherapy.

Patients with cancer of the colon which has spread (metastasised).

To find and test new stratification tools (ways of dividing patients into different groups) in patients who have microsatellite stable RAS mutant metastatic colorectal cancer.

Advanced/metastatic renal cell carcinoma (kidney cancer).

The purpose of this trial is to assess the safety and efficacy of the drug lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of participants with advanced renal cell carcinoma.

Cervical cancer

The purpose of the study is to investigate if Tisotumab Vedotin (HuMax®-TF-ADC) is safe and has an additive effect when used with other anti-cancer medications in the treatment of recurrent or advanced cervical cancer.

Patients with advanced stage RET-rearranged NSCLC, treated with at least one platinum based systemic chemotherapy regimen.

The primary objective is to assess the efficacy of alectinib in terms of best overall response (OR) assessed by RECIST 1.1., from the start of trial treatment across all time points until the end of trial treatment

For patients with non-small cell lung cancer (NSCLC) who are unsuitable for surgery or stereotactic ablative body radiation therapy (SABR)

The primary objective of this study is to assess the safe delivery of an achievable level of dose escalation in a dose‐escalated and
intensified radiation therapy regime delivered via VMAT/IMRT and focussed on the GTV, by the
proportion of grade ≥3 toxicities per NCI‐CTCAE V4 determined to be related to radiation
therapy.

Metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC)

The purpose of this study is to create an international, population-based,
prospective registry of minimum 5,000 men with advanced prostate cancer.

Paediatric patients with Chronic Myeloid Leukemia.

To establish the efficacy, safety, and tolerability of bosutinib.

CD22-positive acute lymphocytic leukemia (ALL)